HK1214814A1 - 類視色素相關之孤兒受體伽瑪 調節劑及其治療自身免疫性疾病和炎症性疾病的用途 - Google Patents

類視色素相關之孤兒受體伽瑪 調節劑及其治療自身免疫性疾病和炎症性疾病的用途

Info

Publication number
HK1214814A1
HK1214814A1 HK16102705.4A HK16102705A HK1214814A1 HK 1214814 A1 HK1214814 A1 HK 1214814A1 HK 16102705 A HK16102705 A HK 16102705A HK 1214814 A1 HK1214814 A1 HK 1214814A1
Authority
HK
Hong Kong
Prior art keywords
ror
gamma
retinoid
modulators
autoimmune
Prior art date
Application number
HK16102705.4A
Other languages
English (en)
Inventor
Fangbin Han
Hui Lei
Xichen Lin
Qinghua Meng
Yonghui Wang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49709687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1214814A1 publication Critical patent/HK1214814A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16102705.4A 2012-12-06 2016-03-09 類視色素相關之孤兒受體伽瑪 調節劑及其治療自身免疫性疾病和炎症性疾病的用途 HK1214814A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2012001636 2012-12-06
CN2013000182 2013-02-25
CN2013000803 2013-07-01
PCT/EP2013/075594 WO2014086894A1 (en) 2012-12-06 2013-12-05 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
HK1214814A1 true HK1214814A1 (zh) 2016-08-05

Family

ID=49709687

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102705.4A HK1214814A1 (zh) 2012-12-06 2016-03-09 類視色素相關之孤兒受體伽瑪 調節劑及其治療自身免疫性疾病和炎症性疾病的用途

Country Status (33)

Country Link
US (1) US10005731B2 (zh)
EP (2) EP2928885B1 (zh)
JP (1) JP6279605B2 (zh)
KR (1) KR20150092244A (zh)
CN (1) CN105121430B (zh)
AR (1) AR093818A1 (zh)
AU (1) AU2013354109B2 (zh)
BR (1) BR112015013137B1 (zh)
CA (1) CA2894016C (zh)
CL (1) CL2015001557A1 (zh)
CR (1) CR20150302A (zh)
CY (1) CY1118932T1 (zh)
DK (1) DK2928885T3 (zh)
EA (1) EA026437B1 (zh)
ES (1) ES2626390T3 (zh)
HK (1) HK1214814A1 (zh)
HR (1) HRP20170638T1 (zh)
HU (1) HUE033212T2 (zh)
IL (1) IL239082A0 (zh)
LT (1) LT2928885T (zh)
ME (1) ME02696B (zh)
MX (1) MX2015007180A (zh)
PE (1) PE20151144A1 (zh)
PH (1) PH12015501244A1 (zh)
PL (1) PL2928885T3 (zh)
PT (1) PT2928885T (zh)
RS (1) RS55875B1 (zh)
SG (1) SG11201504200TA (zh)
SI (1) SI2928885T1 (zh)
TW (1) TW201427959A (zh)
UY (1) UY35174A (zh)
WO (1) WO2014086894A1 (zh)
ZA (1) ZA201503666B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
MX2016015630A (es) * 2014-05-28 2017-04-25 Glaxosmithkline Ip Dev Ltd Nuevos compuestos.
MX2016015631A (es) * 2014-05-28 2017-04-25 Glaxosmithkline Ip Dev Ltd Nuevos compuestos.
JP2017516800A (ja) 2014-05-28 2017-06-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
CN104292208A (zh) * 2014-09-09 2015-01-21 上海师范大学 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201625588A (zh) * 2014-11-05 2016-07-16 第一三共股份有限公司 環狀胺衍生物
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3377482B1 (en) * 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2018011201A1 (en) 2016-07-13 2018-01-18 Leo Pharma A/S Heteroaromatic modulators of the retinoid-related orphan receptor gamma
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途
US11001552B2 (en) 2017-07-18 2021-05-11 Lonza Ltd Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester
AR112461A1 (es) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN108752185A (zh) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 一种1-氟-环戊甲酸的合成方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
CN110862319A (zh) * 2019-12-04 2020-03-06 深圳振强生物技术有限公司 奥扎格雷杂质的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
JP5178526B2 (ja) * 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
JP5902029B2 (ja) 2011-04-28 2016-04-13 日本たばこ産業株式会社 アミド化合物およびその医薬用途
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
RU2014113926A (ru) 2011-09-09 2015-10-20 Нью Йорк Юниверсити АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
EP2841416A1 (en) 2012-04-27 2015-03-04 Glaxo Group Limited Novel compounds
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US10286000B2 (en) 2013-10-25 2019-05-14 St. Jude Children's Research Hospital, Inc. Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
EP3060553A4 (en) 2013-10-25 2017-03-29 Glaxosmithkline LLC Novel compounds
MX2016015630A (es) 2014-05-28 2017-04-25 Glaxosmithkline Ip Dev Ltd Nuevos compuestos.
JP2017516800A (ja) 2014-05-28 2017-06-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
MX2016015631A (es) 2014-05-28 2017-04-25 Glaxosmithkline Ip Dev Ltd Nuevos compuestos.

Also Published As

Publication number Publication date
SI2928885T1 (sl) 2017-06-30
PT2928885T (pt) 2017-06-30
JP2016501250A (ja) 2016-01-18
CN105121430B (zh) 2017-06-16
BR112015013137B1 (pt) 2022-05-10
EP3219711A1 (en) 2017-09-20
CY1118932T1 (el) 2018-01-10
KR20150092244A (ko) 2015-08-12
BR112015013137A2 (pt) 2017-07-11
TW201427959A (zh) 2014-07-16
CA2894016C (en) 2020-12-22
CL2015001557A1 (es) 2015-10-02
EA201591059A1 (ru) 2015-09-30
AU2013354109B2 (en) 2016-06-16
US20150299121A1 (en) 2015-10-22
IL239082A0 (en) 2015-07-30
JP6279605B2 (ja) 2018-02-14
ZA201503666B (en) 2016-02-24
ME02696B (me) 2017-10-20
HUE033212T2 (hu) 2017-11-28
CN105121430A (zh) 2015-12-02
PH12015501244A1 (en) 2015-08-10
AR093818A1 (es) 2015-06-24
EP2928885A1 (en) 2015-10-14
EP2928885B1 (en) 2017-03-22
AU2013354109A1 (en) 2015-06-11
RS55875B1 (sr) 2017-08-31
ES2626390T3 (es) 2017-07-24
PL2928885T3 (pl) 2017-09-29
LT2928885T (lt) 2017-05-25
US10005731B2 (en) 2018-06-26
SG11201504200TA (en) 2015-06-29
HRP20170638T1 (hr) 2017-06-30
MX2015007180A (es) 2015-10-14
DK2928885T3 (en) 2017-05-15
UY35174A (es) 2014-06-30
CA2894016A1 (en) 2014-06-12
EA026437B1 (ru) 2017-04-28
WO2014086894A1 (en) 2014-06-12
CR20150302A (es) 2015-08-10
PE20151144A1 (es) 2015-08-02

Similar Documents

Publication Publication Date Title
HK1214814A1 (zh) 類視色素相關之孤兒受體伽瑪 調節劑及其治療自身免疫性疾病和炎症性疾病的用途
HK1209117A1 (zh) 作為孤兒核受體 γ調節物的經甲醯胺或磺醯胺取代的噻唑及相關衍生物
EP3091074A4 (en) T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
HRP20181398T1 (hr) Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
EP2844247A4 (en) ROR MODULATORS AND ITS USES
HK1210430A1 (zh) 調節免疫細胞激活的試劑及其使用方法
IL247457B (en) Adapted Cell Therapy Using an Orphan Gamma-Related Retinoic Acid Receptor Agonist and Related Therapeutic Methods
EP2830548A4 (en) ORAL DEVICE COMPRISING A BOTTLE SIMULATOR AND METHOD FOR USE THEREOF
EP2815769A4 (en) PHARMACEUTICAL USE OF FAM19A5 IN A GLIOGENESIS REGULATION
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
RS59934B1 (sr) Modulatori nuklearnih receptora (ror) za lečenje inflamatornih i autoimunih oboljenja
EP2799539A4 (en) HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE WITH FIXED POINT, AND USE THEREOF
EP2646430A4 (en) MODULATORS OF THE CHEMOKINE RECEPTOR CXCR4 AND USES THEREOF
EP2827819A4 (en) THERAPEUTIC SKIN LAUNDRY DEVICE, AND ASSOCIATED SYSTEMS AND METHODS
EP2844260A4 (en) ROR MODULATORS AND ITS USES
EP2970223A4 (en) Novel Modulators of 5-Hydroxypropylamine Receptor 7 Activity and Methods of Use
IL236062A0 (en) In vitro diagnostic device and its uses
EP2895474A4 (en) LEGIBLE MODULATORS AND METHOD OF USE THEREFOR
IL237719B (en) Antibodies specific to (hiapp) human islet amylid polypeptide and their uses
TH1501003076A (th) ตัวคุมของตัวรับที่ยังไม่ได้ระบุจำแนกประเภทที่เกี่ยวข้องกับเรตินอยด์ชนิดแกมมา (ror-แกมมา) สำหรับใช้ในการรักษาโรคทางภูมิต้านตนเองและโรคที่มีอาการอักเสบ
AU2012900762A0 (en) Back Support and Rehabilitation Device
AU2012900775A0 (en) Therapeutic and diagnostic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211204